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If channel inhibitor. Ivabradine is a selective antagonist of funny
channels with anti-anginal and anti-ischaemic properties that
provides pure heart rate reduction, reducing the diastolic depolar-
ization slope, without altering other cardiac and haemodynamic
parameters. There is consistent evidence that ivabradine is effective
in reducing angina pectoris symptoms and myocardial ischemia. At
approved doses ivabradine is safe, improves exercise performance
and reduces heart rate has a positive effect on heart rate. Available
literature supports its use in the management of patients with stable
CAD and chronic HF. Recent studies have casted doubts on the safety
of non approved high doses of ivabradine for the treatment of
patients with CAD and without clinical HF, but have shown no
concerns on the doses approved for clinical use.
Gene therapy. Therapeutic angiogenesis has been focused on the
administration of the vascular endothelial growth factor (VEGF) and
ﬁbroblast growth factor (FGF). At present, VEGF and FGF have been the
most extensively studied angiogenic agents. Growth factor proteins may
be given directly or through gene-based approaches using naked
plasmid deoxyribonucleic acid or a viral vector that encodes the gene
so that it can be taken up by the recipient endothelial cells. These agents
may be administered directly to the myocardium by epicardial,
endocardial, or intracoronary injection. The studies using these agents
have so far achieved inconclusive results.
Enhanced external counterpulsation. EECP is a novel treatment
for patients with ischemic heart disease and refractory angina. EECP
is performed by encircling the legs with compression devices that
inﬂate during diastole to 300 mm Hg and deﬂate them during
systole. This counterpulsation unloads the left ventricle during
ventricular systole and improves coronary blood ﬂow during
diastole. In a randomised clinical trial 139 patients clinical symptoms
and treadmill exercise times improved and a variable effect on
myocardial perfusion was found. However, the absence of proper
blinding during this study makes the results uncertain.
Spinal cord stimulation. Spinal cord stimulation, is an effective
method for pain relief in patients with refractory angina not
amenable to revascularisation. The treatment involves placing a
stimulating electrode in the dorsal epidural space at the C7–T1 level.
It has been suggested that spinal cord stimulation exerts beneﬁcial
effects by decreasing pain and sympathetic tone. Early study with
spinal cord stimulators suggested an improvement in total exercise
time and time to angina. However, in another trial the anginal
symptoms decreased even after discontinuation of therapy suggest-
ing a most likely primary analgesic effect of this treatment.
Despite signiﬁcant advances in the percutaneous treatment of
coronary artery disease medical management represents the treat-
ment of choice in most patients. Newer therapeutic agents have been
shown to be safe and effective when used in monotherapy or in
association with the existing classical antianginals.
doi:10.1016/j.ijcme.2015.05.011
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Obesity is a key factor in the development of insulin resistance
(IR), cardiovascular disease, hypertension, type 2 diabetes etc. Given
the near epidemic incidence of obesity in western society there is a
clear need for effective treatment options. Mineralocorticoid receptor
(MR) blockade has shown signiﬁcant promise in transgenic mouse
models of obesity in limiting IR and adipocyte dysfunction, a disease
that is independent of classical MR actions (renal). Female 10-week-
old C57bl6 mice were fed with normal chow or a high fat (HF) diet
for 12 weeks. Mice fed HF diet were concomitantly treated for
12 weeks with drospirenone (DRSP, 6 mg/kg/day), a potent MR
antagonist with antiadipogenic activity, or spironolactone (SPIRO,
20 mg/kg/day). Mice fed HF diet showed a signiﬁcant increase in
total body weight, fat mass, mean adipocyte size, expression of white
adipose tissue (WAT) marker genes and showed impaired glucose
tolerance after intraperitoneal plasma glucose tolerance test. DRSP
and SPIRO prevented weight gain and white fat mass expansion
induced by HF diet in parametrial, perivescical, and inguinal depots
without affecting interscapular fat pad weight. Magnetic Resonance
Imaging (MRI) conﬁrmed that MR antagonists blocked the HF diet-
driven expansion of abdomino-pelvic (parametrial and perivescical)
fat volume. High levels of MR mRNA were detected in all depots of
adipose tissue. HF fed mice showed no increase in heart or kidney
weight and tissue ﬁbrosis. Cardiac macrophage recruitment and
osteopontin staining was increased in hearts of HF fed mice and
reversed by both MR antagonists. Moreover, both DRSP and SPIRO
prevented the impaired glucose tolerance in mice fed HF diet, and
countered HF diet-induced up-regulation of WAT markers transcripts
and adipocyte hypertrophy. Importantly, MR antagonists increased
uncoupling protein 1 (UCP-1) positive brown-like adipocyte content
in WAT, and improved metabolic activity of adipose tissue, as
indicated by PET/CT imaging. In keeping with this, MR antagonism
signiﬁcantly increased expression of brown-like adipocyte marker
genes such PRDM16, CIDEA, beta-3 adrenergic receptor (ADRB3) and
UCP-1 in all WAT depots analysed. In exploring the mechanism, we
demonstrated that MR antagonism induced brown adipose tissue
(BAT) markers, and reduced the autophagic rate, a key remodelling
process in adipocyte differentiation, in WAT depots in vivo as well as
in primary cultured adipocytes. We conclude that adipocyte MR
regulates BAT-like remodeling of WAT through modulation of
autophagy. MR blockade therefore has promise as a novel therapeu-
tic option for the prevention of metabolic dysfunctions and the
cardiac consequences of obesity.
doi:10.1016/j.ijcme.2015.05.012
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In clinical trials, mineralocorticoid receptor (MR) antagonists
decrease cardiovascular ischemia and mortality suggesting a beneﬁ-
cial role of MR inhibition in the vasculature. We have shown that
human coronary and umbilical endothelial cells (HUVEC) express
functional MR. In endothelial cells MR activation by aldosterone
promoted transcription of ICAM-1. Most importantly cell adhesion
assays demonstrated that aldosterone promotes leukocyte adhesion
to ECs, an effect that was inhibited by spironolactone and ICAM-1
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blocking antibody. These data support that MR activation in human
endothelial cells promotes ICAM-1-mediated leukocyte-EC adhesion,
an important step in early atherosclerosis lesion formation. To further
explore the mechanisms for MR-mediated EC activation, we now
demonstrate that MR activation up-regulates VCAM-1 and E-selectin
mRNA expression (2 and 3.5 fold respectively), whereas P-selectin is
not regulated by MR. We also further explored the mechanism of MR-
mediated regulation of endothelial ICAM-1 expression. In transient
transfection experiments performed in HUVEC, we have shown that
aldosterone is able to activate (2 fold) a 3 Kb promoter region
upstream the transcription start site of human ICAM-1 gene. Co-
incubation with spironolactone was able to inhibit the effect of
aldosterone, conﬁrming the presence of elements responsive to
signaling pathway(s) activated by MR. In order to localize and
characterize MR responsive cis-element(s) and the corresponding
transcription factor(s) binding to this regulatory region, ﬁve 5′-
deletion constructs of ICAM-1 promoter were subcloned in a vector
upstream of the luciferase gene. Data of transcriptional activity
showed the presence of regulatory element(s) required for ICAM-1
expression via MR in the promoter region between nt-872 and -1141.
Bioinformatics analysis of this region revealed the presence of four
different highly conserved regulatory elements: three SP1 binding
sites, one NF-κB binding site, one AP1 binding site and one GRE/MRE.
The role of these transcription factors in MR-mediated regulation of
ICAM-1 expression was investigated using c-JUN and IKBα dominant
negative constructs. Blocking of either c-Jun or NF-κB pathway
resulted in a marked reduction of the aldosterone effect on ICAM-1
promoter activity, suggesting the involvement of these transcription
factors. These studies explore the molecular mechanism for the pro-
inﬂammatory effects of MR activation in the vasculature that may
contribute to explain the protective effects of MR antagonists in
clinical trials. Moreover to better understand the crosstalk between
MR activation and ICAM1 in the development of atherosclerosis
lesions, we developed a mouse model double KO for ApoE and ICAM1,
where we are currently studying the pro-atherogenic effects of
aldosterone.
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Statins are the most commonly prescribed drugs to treat lipid
disorders and reduce cardiometabolic risk. However, the use of
natural compounds may represent a valid support for statin-
intolerant patients. We aimed to assess the effect of bergamot-
derived polyphenolic fraction (BPF) in modulating serum cholesterol
and biomarkers of vascular oxidative stress in patients with mixed
hyperlipidemia either untreated or treated with rosuvastatin.
A prospective, open-label, parallel group, placebo-controlled
study on 77 patients with elevated serum LDL-C and triglycerides
was designed. Patients were randomly assigned to a control group
receiving placebo (n = 15), two groups receiving orally rosuvastatin
(10 and 20 mg/daily for 30 days n = 16 for each group), a group
receiving BPF alone orally (1000 mg/daily for 30 days; n = 15) and a
group receiving BPF (1000 mg/daily given orally) plus rosuvastatin
(10 mg/daily for 30 days; n = 15).
Both doses of rosuvastatin and BPF reduced total cholesterol, LDL-
C, the LDL-C/HDL-C ratio and urinary mevalonate in hyperlipidemic
patients, compared to control group. The cholesterol lowering effect
was accompanied by reductions of malondialdehyde, oxyLDL recep-
tor LOX-1 and phosphoPKB, which are all biomarkers of oxidative
vascular damage, in peripheral polymorphonuclear cells.
Addition of BPF to rosuvastatin signiﬁcantly enhanced
rosuvastatin-induced effect on serum lipemic proﬁle compared to
rosuvastatin alone, an effect associated to signiﬁcant reductions of
biomarkers used for detecting oxidative vascular damage, suggesting
a multiaction synergistic potential for BPF in statin-taking patients.
BPF may be an alternative therapeutic strategy for hyperlipidemia in
patients with statin-induced side effects.
doi:10.1016/j.ijcme.2015.05.014
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The occurrence of Metabolic Syndrome (MS) represents an
independent risk factor for developing cardiovascular disease states
in patients suffering from type 2 diabetes mellitus. Moreover, both
the size of LDL particles and liver dysfunction identiﬁed as non-
alcoholic fatty liver disease (NAFLD) represent important biomarkers
for the development of cardiometabolic risk in patients with MS. We
studied the effect of bergamot polyphenolic fraction (BPF) in patients
with MS and NAFLD. 107 patients were enrolled at the San Raffaele
IRCCS (Rome). All of them showed ultrasonograﬁc evidences of
NAFLD and at least three out of ﬁve previous identiﬁed criteria for
the diagnosis of MS. Patients were divided into two groups: one
receiving placebo and the second receiving BPF 650 mg twice a day
for 120 consecutive days. In the group receiving BPF 650 mg twice a
day, a signiﬁcant reduction of fasting plasma glucose, serum LDL
cholesterol and triglycerides alongside with an increase of HDL
cholesterol was found. This effect was accompanied by a signiﬁcant
reduction of both ultrasonographic and metabolic biomarkers of
NAFLD as well as by a decrease of small dense LDL particles.
Overall, our data show that bergamot-deriving polyphenolic
fraction given in patients with MS and NAFLD, leads to concomitant
amelioration of the lipemic and glycemic serum proﬁles and to
substantial reduction of liver steatosis. This effect, alongside with a
reduction of pro-atherogenic small dense LDL and enhancement of
anti-atherogenic high dense HDL, shed new light on the potential use
of bergamot-extract for reducing cardiometabolic risk in patients
with MS.
doi:10.1016/j.ijcme.2015.05.015
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